about
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.The next generation of immunotherapy: keeping lung cancer in check.Immune checkpoint blockade in lung cancer.A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.The Role of the Estrogen Pathway in the Tumor Microenvironment.Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer
P50
Q37688658-EC0568AE-CC5E-4653-BE68-B4B0F0307BC2Q38266308-80AE7802-E04C-40A6-BFD2-CC6C5864C3D1Q38824489-547938B7-D44D-440F-91B2-5422A18A60C8Q38943927-907B3728-E660-4B72-9C6A-9647351F6E4DQ47887010-250783CE-35AF-4561-BAF4-1B80F21CCBFDQ49803828-37A1F72A-F742-4B45-A472-D85167EBC473Q95274116-2A2A232F-E9CA-4C24-AF53-5B1D4C2222BD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ashwin Somasundaram
@ast
Ashwin Somasundaram
@en
Ashwin Somasundaram
@es
Ashwin Somasundaram
@nl
type
label
Ashwin Somasundaram
@ast
Ashwin Somasundaram
@en
Ashwin Somasundaram
@es
Ashwin Somasundaram
@nl
prefLabel
Ashwin Somasundaram
@ast
Ashwin Somasundaram
@en
Ashwin Somasundaram
@es
Ashwin Somasundaram
@nl
P106
P31
P496
0000-0003-3167-406X